Immuneering annual meeting: all three director nominees elected, auditor ratified

Immuneering Corp

69.1% of outstanding Class A common stock represented at June 13, 2025 meeting.
Ann E. Berman, Diana F. Hausman, M.D., and Thomas J. Schall, Ph.D. elected as Class I directors.
RSM US LLP ratified as independent auditor for fiscal year ending December 31, 2025.
Broker non-votes of 10,009,639 on director elections; no broker non-votes on auditor ratification.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.